NCT00719043 - Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years | Biotech Hunter

Enrollment

841

Participants

Timeline

Start Date

July 11, 2008

Primary Completion Date

April 22, 2010

Study Completion Date

February 18, 2011

Conditions

Influenza

Interventions

BIOLOGICAL

A/turkey H5N1 vaccine

Administered as an intramuscular (IM) injection

BIOLOGICAL

Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)

Administered as an intramuscular (IM) injection

BIOLOGICAL

Placebo

Administered as an intramuscular (IM) injection

Trial Locations (13)

27103

GSK Investigational Site, Winston-Salem

37620

GSK Investigational Site, Bristol

59801

GSK Investigational Site, Missoula

60610

GSK Investigational Site, Chicago

64114

GSK Investigational Site, Kansas City

70006

GSK Investigational Site, Metairie

76135

GSK Investigational Site, Fort Worth

78705

GSK Investigational Site, Austin

80239

GSK Investigational Site, Denver

01757

GSK Investigational Site, Milford

B3K 6R8

GSK Investigational Site, Halifax

H2K 4L5

GSK Investigational Site, Montreal

J1H 4J6

GSK Investigational Site, Sherbrooke